JOHN J. PARTRIDGE,JOHN COLUCCI,YVES GAREAU,MICHEL THERIEN,ROBERT ZAMBONI,BARRY HAFKIN,ANTHONY MARFAT,HELMI ZAGHDANE
申请号：
MX2014015855
公开号：
MX2014015855A
申请日:
2013.06.19
申请国别(地区):
MX
年份:
2015
代理人:
摘要：
In part, the present disclosure is directed to derivatives of (E)-N-methy1-N-(( 3-methylta 1,8-naphthyndin-3-y1)acrylamide compounds with significant solubility, solid state stability and bioavailability profiles. Said compounds have been found to be effective inhibitors of bacterial fatty acid metabolism via the effective inhibition of FabL hi addition, certain compounds are shown to be stable towards gamma radiation sterilization treatments, and are thus well-suited to the production of a sterile formulation for use in the treatment of illnesses caused by bacterial infections.En parte, la presente descripción está dirigida a derivados pro-fármaco de los compuestos (E)-N-metil-N-((3-metilbenzofuran-2- il)metil)-3-(7-oxo-5,6,7,8-tetrahidro-1,8-naftiridin-3-il)acrilam ida con perfiles de solubilidad y biodisponibilidad significativos.
